Although molecularly targeted cancer therapies are generally safe and more effective than previous treatment options, some serious adverse events can occur.
Americans' excessive alcohol use contributes to thousands of deaths each year, and the majority who die are working-age adults, according to a report published in the March 14 issue of the US Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.
For Medicare beneficiaries with prostate cancer, stereotactic body radiation therapy is less expensive than intensity-modulated radiation therapy, but is associated with more genitourinary toxicity, according to a study published online March 10 in the Journal of Clinical Oncology.
Higher concentrations of serum 25-hydroxyvitamin D are associated with lower mortality from breast cancer, according to a meta-analysis published in the March issue of Anticancer Research.
About one-third of U.S. oncologists report being satisfied with work-life balance, which is lower than for other medical specialties, according to a study published online March 10 in the Journal of Clinical Oncology.
For patients with chronic disease, health providers do not routinely provide health education, according to a study published March 6 in the U.S. Centers for Disease Control and Prevention's Preventing Chronic Disease.
Inconsistencies between ClinicalTrials.gov and medical journals’ reporting are raising questions about the editing and disseminating process.
Body fatness, marked by body mass index, is probably associated with an increased risk of ovarian cancer, according to a report published March 11 by the World Cancer Research Fund and the American Institute for Cancer Research.
A US Food and Drug Administration advisory panel is considering whether to delay the Pap test and use a human papillomavirus (HPV) test as a first step in cervical cancer screening. Specifically, the agency's Medical Devices Advisory Committee Microbiology Panel is being asked to evaluate the cobas HPV test made by Roche Molecular Systems.
The phosphatidylinositol-3-kinase delta inhibitor idelalisib shows antitumor activity in patients with indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia, according to two studies published in the March 13 issue of the New England Journal of Medicine.